Pelthos Therapeutics Inc. (PTHS) compared with its closest peers (LENZ, BDTX, TCRX, PROK, KLRS). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $147.05M | -5.6 |
| Black Diamond Therapeutics, Inc. (BDTX) | $126.40M | 6.3 |
| TScan Therapeutics, Inc. (TCRX) | $101.28M | -1.0 |
| ProKidney Corp. (PROK) | $99.70M | -29.8 |
| Kalaris Therapeutics Inc (KLRS) | $98.79M | -2.9 |
| Atara Biotherapeutics, Inc. (ATRA) | $98.07M | 7.0 |
| Cognition Therapeutics, Inc. (CGTX) | $95.07M | -4.2 |
| Outlook Therapeutics, Inc. (OTLK) | $78.25M | — |
| Champions Oncology, Inc. (CSBR) | $70.30M | 17.6 |
| Cardiff Oncology, Inc. (CRDF) | $68.47M | -4.1 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
PTHS overview · PTHS earnings · PTHS financials · PTHS KPIs · PTHS investor relations · PTHS ownership · PTHS filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.